Mednet Logo
HomeQuestion

For women with metastatic HER2 + breast cancer who achieve a complete response, how long do you continue on HER2-directed therapies?

1
3 Answers
Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

In nearly all cases, I would continue therapy until progression or unacceptable toxicity. Multiple studies have found an improvement in PFS and.or OS by continuing trastuzumab (or other HER2 inhibitor) after progression on trastuzumab.. Ask yourself this.....if continuing BEYOND progression is helpf...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · UT Southwestern Medical Center

I typically continue trastuzumab even after a complete response, although I might consider changing the backbone to avoid toxicity. For example, for someone with hormone receptor positive, HER2-positive disease who achieves a durable complete response on paclitaxel-trastuzumab, I might consider a tr...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · MOSC Medical College Kolenchery

I think one unanswered question is how to manage women with HER2+ MBC who are exceptional responders with no active site of disease and are on single agent herceptin for 5+ years. Would you consider stopping the drug (drug holiday) and careful monitoring for disease progression? An MD Anderson regis...

Register or Sign In to see full answer

For women with metastatic HER2 + breast cancer who achieve a complete response, how long do you continue on HER2-directed therapies? | Mednet